Recombinant alpha-1 antitrypsin for the treatment of exacerbations of cystic fibrosis

Name: Dr Paul King
Partner Organisation: Monash Health
Project Start Date: January 1, 2025
THIS PROJECT IS NOW COMPLETE
Aims:
Pulmonary exacerbations in cystic fibrosis (CF) are episodes of acute lung inflammation that drive symptoms and irreversible loss of lung function, yet current treatments do not target the underlying inflammation.
This research program addresses this gap by repurposing alpha-1 antitrypsin (AAT), a naturally anti-inflammatory protein, for acute use in CF exacerbations. The team has developed a novel, low-cost recombinant AAT that can be produced at scale and has shown strong anti-inflammatory effects in early studies. This project will test its ability to reduce inflammation in clinical samples from people with CF, laying the groundwork for clinical trials and the first targeted anti-inflammatory therapy for CF.
Outcomes:
The research team has developed a recombinant form of AAT that can be produced in large quantities at low cost, overcoming the issues that have restricted the use of blood-derived AAT. Previous studies have shown that it can effectively reduce lung inflammation in laboratory and animal models of worsening lung disease. These findings provide a strong basis for further research and support the development of future clinical trials to assess whether this treatment could help people with CF during flare-ups.
Research translation and Impact: TBC
